Accretive Wellness third quarter net services revenue increases 38 percent to $218.

As a complete consequence of these factors, the business expects adjusted net income per diluted common share of $0.42 to $0.44 for fiscal year 2011.. Accretive Wellness third quarter net services revenue increases 38 percent to $218.9 million Accretive Health, Inc. , a leading provider of extensive end-to-end healthcare revenue routine management services and people health management providers infrastructure, today announced financial outcomes for the 3rd quarter ended September 30, 2011.We are excited to start Epoprostenol for Injection with the Accredo team, and can leverage their coordinated individual support system and intensive encounter with PAH therapies, including epoprostenol, said Shal Jacobovitz, president of Actelion Pharmaceuticals US, Inc. This partnership will help ensure that patients have the support they need and the access to this convenient treatment choice for moderate to severe PAH. Accredo provides an enhanced degree of personalized service to patients with chronic and complex disease, and can provide call center, nursing and reimbursement support services for individuals using Epoprostenol for Injection and their healthcare providers.